Commercial Assay Aids Physicians in Tamoxifen Drug Monitoring
By LabMedica International staff writers Posted on 30 Dec 2015 |
Image: Immunohistochemistry of an estrogen receptor-positive breast cancer surgical pathology specimen; most of the cancer cell nuclei stain strongly positive (dark brown) for estrogen receptor (ER) (Photo courtesy of Dr. Ronald S. Weinstein, MD).
A laboratory developed test could help assess levels of several tamoxifen drug metabolites in a blood specimen which is important as five years of therapy with tamoxifen has been the standard of care for women with early stage, estrogen-receptor-positive (ER+) breast cancer following "curative" surgery.
Tamoxifen, taken for five years, reduces the risk of developing invasive breast cancer by about 50% in postmenopausal women who are at increased risk of getting the disease. However, compliance is an issue and patients could be further helped from precise prescribing as side effects from Tamoxifen are known to include mood swings, depression, and loss of libido, cataracts, blood clots, strokes, bone loss and the increase risk of endometrial and uterine cancer.
Medical experts from Quest Diagnostics (Madison, NJ, USA) show how the laboratory developed test could help assess levels of several tamoxifen drug metabolites in a blood specimen. The scientists evaluated the blood serum from 155 women who were on 20 mg/day tamoxifen for more than six months. The patient population exhibited a wide range of concentrations of tamoxifen and its metabolites during therapy, reflecting individual differences in the ability to metabolize the drug.
The test is based on a tandem mass spectrometry, (LC-MS/MS) a technique used by world-class laboratories to measure hormones and vitamin D, the test allows physicians, for the first time, to employ a commercially available therapeutic drug monitoring approach for their tamoxifen-treated patients. The test may also help physicians assess noncompliance with tamoxifen therapy, a common problem given side effects such as weight gain or loss.
Nigel Clarke, PhD, coauthor and a senior scientific expert responsible for technology innovation for Quest Diagnostics, said, “When people think of personalized medicine or precision medicine they often think of genetic testing to assess a drug against a gene variant. But a growing area in personalized medicine is the use of qualitative enzyme or drug metabolite testing to assess the biological impact of a drug rather than the indirect influence of genes.” The study was presented on December 11, 2015, at the San Antonio Breast Cancer Symposium held in San Antonio (TX, USA).
Related Links:
Quest Diagnostics
Tamoxifen, taken for five years, reduces the risk of developing invasive breast cancer by about 50% in postmenopausal women who are at increased risk of getting the disease. However, compliance is an issue and patients could be further helped from precise prescribing as side effects from Tamoxifen are known to include mood swings, depression, and loss of libido, cataracts, blood clots, strokes, bone loss and the increase risk of endometrial and uterine cancer.
Medical experts from Quest Diagnostics (Madison, NJ, USA) show how the laboratory developed test could help assess levels of several tamoxifen drug metabolites in a blood specimen. The scientists evaluated the blood serum from 155 women who were on 20 mg/day tamoxifen for more than six months. The patient population exhibited a wide range of concentrations of tamoxifen and its metabolites during therapy, reflecting individual differences in the ability to metabolize the drug.
The test is based on a tandem mass spectrometry, (LC-MS/MS) a technique used by world-class laboratories to measure hormones and vitamin D, the test allows physicians, for the first time, to employ a commercially available therapeutic drug monitoring approach for their tamoxifen-treated patients. The test may also help physicians assess noncompliance with tamoxifen therapy, a common problem given side effects such as weight gain or loss.
Nigel Clarke, PhD, coauthor and a senior scientific expert responsible for technology innovation for Quest Diagnostics, said, “When people think of personalized medicine or precision medicine they often think of genetic testing to assess a drug against a gene variant. But a growing area in personalized medicine is the use of qualitative enzyme or drug metabolite testing to assess the biological impact of a drug rather than the indirect influence of genes.” The study was presented on December 11, 2015, at the San Antonio Breast Cancer Symposium held in San Antonio (TX, USA).
Related Links:
Quest Diagnostics
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines